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 A case report of angiosarcoma of the scalp successfully treated with pazopanib 1 
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To the Editor: Angiosarcoma of the scalp has one of the worst prognoses among 24 
malignant skin tumors 1. Standard treatment guidelines for angiosarcoma do not 25 
currently exist 1. To the best of our knowledge, this is the first case of angiosarcoma of 26 
the scalp that responded significantly to oral pazopanib administration. 27 
 A 63-year-old man presented with scalp tumors that had developed two 28 
months before. Histopathologic examination revealed atypical, hyperchromatic 29 
endothelial cells, which were positive for CD31, CD34, D2-40, and VEGFR2, and 30 
formed vascular channels. The two tumors, 60 and 20 mm in diameter, were excised 31 
with negative surgical margins; however, four additional surgical operations were 32 
required to remove multiple recurrences. Subsequently, weekly docetaxel (25 mg/m2, on 33 
days 1, 8, and 15, and every 4 weeks thereafter) was administered at 8 months after 34 
initial onset, but failed to suppress the development of further cutaneous tumors. 35 
Therefore, intravenous recombinant interleukin-2 (7 × 105 U/day) combined with a 36 
100-Gy electron beam irradiation was administered for 11-18 months after onset. 37 
However, new tumors grew outside the area of irradiation. At 18 months after onset, 38 
multiple ulcers were visible on the patient’s scalp, a 30 × 20 mm indurated plaque on 39 
the left cheek, marked edema of the face (Fig. 1A), and the involvement of multiple 40 
cervical, mandibular, and intraparotid lymph nodes (Fig. 2A). 41 
 Owing to the refractory tumors, pazopanib treatment was initiated at a dose of 42 
800 mg once daily. At day 3 of pazopanib treatment, edema of the face began to subside, 43 
and the patient began to open both eyes; the edema finally disappeared by day 14. The 44 
left cheek indurated plaque completely disappeared (Fig. 1B). In addition, a computed 45 
tomography scan at day 19 showed shrinking of the multiple cervical, mandibular, and 46 
intraparotid lymph nodes (Fig. 2B). Toxic side effects of grade 3 thrombocytopenia and 47 
grade 2 neutropenia were apparent. Pazopanib therapy was discontinued two weeks and 48 
restarted at a reduced dose of 600 mg once daily. Thereafter, grade 3 proteinuria 49 
required dose reduction of 400 mg once daily. However, partial tumor reduction was 50 
maintained for 24 weeks and the patient is now undergoing a pazopanib treatment 51 
without toxic side effects. 52 
 Pazopanib is a multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, 53 
VEGFR-2, VEGFR-3, PDGFR-a/β, and c-kit 2. VEGFR-2 have been found to be 54 
up-regulated in angiosarcoma 3. Angiosarcoma cells in the present case were also 55 
positive for VEGFR-2, suggesting that the signal through VEGFR-2 stimulates tumor. 56 
Accordingly, it is possible that pazopanib leads to clinical improvement by inhibition of 57 
VEGFR-2 tyrosine kinase activity.  58 
 The present case showed the rare toxic effects 4. It is possible that taxane 59 
chemotherapy contributed to these toxic effects. 60 
 Other VEGFR inhibitors (bevacizumab, sorafenib, and sunitinib) have also 61 
been reported to be effective treatments for angiosarcoma 1. Thus, VEGFR inhibitor, 62 
including pazopanib, may be an additional optional for treating angiosarcoma.  63 
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Figure legends 80 
Figure 1: Improvements in edema and erythema and reduction in the left cheek 81 
indurated plaque are seen following pazopanib therapy. (A) Before pazopanib therapy. 82 
(B) 14 days after commencement of pazopanib therapy. 83 
Figure 2: Serial computed tomography scans. Scans show varying responses in multiple 84 
intraparotid lymph nodes (arrows). (A) Before pazopanib therapy. (B) 19 days after 85 
commencement of pazopanib therapy. 86 
 87 
  88 
 89 
